FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W371889377> ?p ?o ?g. }

• W371889377 abstract "1670 Objectives: Assess efficacy of 90Y DOTA TATE therapy beyond standard 6-mo evaluation period, to determine if this treatment could be beneficial in patients with extensive NET. Methods: 36pts treated between 11/2004-12/2006, mean age 52yrs, all with an extensive metastatic neuroendocrine carcinoma. GEP-NET 32 subjects (WHO 2), midgut carcinoid - 20 patients, foregut tumour – pancreas 8. Next 2 pts atypical bronchial carcinoid, additional 2 malignant pheochromocytoma and 4 cases of unknown origin. All patients had received 90Y DOTA TATE. An average overall dose administered was 14,8GBq. Almost all (33pts) had 3 or 4 therapy sessions and 6-8 weeks intervals, 3 subjects had 2 sessions. In each case response was assessed with spiral CT, biochemical profile and evaluation of clinical symptoms. The median TTP of disease and death (if applicable) was evaluated. Results: Overall 117 therapies using 90Y DOTA TATE were given over 25 months without early significant toxicity and side effects within 6 weeks after treatment. Long-lasting renal toxicity was encountered in 2 pts (renal insufficiency after 6 mo). There were 2 deaths before complete therapy, others had median follow-up 15months (range (9-25). Consider RECIST criteria after 6months of complete therapy (36pts applicable) 28% subjects had PR, 61% DS and 11% DP in this period clinically there were 50% pts with PR, 19% with DS and 31% with DP. After 6mo there were additional 2 deaths. Median TTP in those who survived 6mo after last treatment median TTP was 17mo. Twelve months after start of the treatment (18pts applicable) 33% had still PR, 33% had DS and other had DP with median TTP in this group of pts 20mo. By the end of 18mo there were additional 4 cancer deaths. Conclusions: In patients treated with 90Y DOTA TATE, 69% of them had some benefit for at least 6 mo after the end of treatment; additional in group of 18 subjects, 66% of them had benefit at 12mo from this treatment. This was obtained with renal insufficiency in 2 pts after 6mo." @default.
• W371889377 created "2016-06-24" @default.
• W371889377 creator A5004411350 @default.
• W371889377 creator A5004541154 @default.
• W371889377 creator A5005327464 @default.
• W371889377 creator A5010530541 @default.
• W371889377 creator A5044912710 @default.
• W371889377 creator A5054571679 @default.
• W371889377 creator A5065479600 @default.
• W371889377 creator A5069366701 @default.
• W371889377 date "2007-05-01" @default.
• W371889377 modified "2023-10-18" @default.
• W371889377 title "Efficacy of 90Y DOTA TATE therapy in patients with progressive metastatic NETs" @default.
• W371889377 hasPublicationYear "2007" @default.
• W371889377 type Work @default.
• W371889377 sameAs 371889377 @default.
• W371889377 citedByCount "0" @default.
• W371889377 crossrefType "journal-article" @default.
• W371889377 hasAuthorship W371889377A5004411350 @default.
• W371889377 hasAuthorship W371889377A5004541154 @default.
• W371889377 hasAuthorship W371889377A5005327464 @default.
• W371889377 hasAuthorship W371889377A5010530541 @default.
• W371889377 hasAuthorship W371889377A5044912710 @default.
• W371889377 hasAuthorship W371889377A5054571679 @default.
• W371889377 hasAuthorship W371889377A5065479600 @default.
• W371889377 hasAuthorship W371889377A5069366701 @default.
• W371889377 hasConcept C126322002 @default.
• W371889377 hasConcept C141071460 @default.
• W371889377 hasConcept C2776694085 @default.
• W371889377 hasConcept C2778822529 @default.
• W371889377 hasConcept C2779066768 @default.
• W371889377 hasConcept C29730261 @default.
• W371889377 hasConcept C2989005 @default.
• W371889377 hasConcept C2993559085 @default.
• W371889377 hasConcept C71924100 @default.
• W371889377 hasConceptScore W371889377C126322002 @default.
• W371889377 hasConceptScore W371889377C141071460 @default.
• W371889377 hasConceptScore W371889377C2776694085 @default.
• W371889377 hasConceptScore W371889377C2778822529 @default.
• W371889377 hasConceptScore W371889377C2779066768 @default.
• W371889377 hasConceptScore W371889377C29730261 @default.
• W371889377 hasConceptScore W371889377C2989005 @default.
• W371889377 hasConceptScore W371889377C2993559085 @default.
• W371889377 hasConceptScore W371889377C71924100 @default.
• W371889377 hasOpenAccess W371889377 @default.
• W371889377 hasRelatedWork W2011567397 @default.
• W371889377 hasRelatedWork W2023421708 @default.
• W371889377 hasRelatedWork W2066616838 @default.
• W371889377 hasRelatedWork W2092047830 @default.
• W371889377 hasRelatedWork W2165332129 @default.
• W371889377 hasRelatedWork W2315057995 @default.
• W371889377 hasRelatedWork W2321417046 @default.
• W371889377 hasRelatedWork W2414851723 @default.
• W371889377 hasRelatedWork W2546213836 @default.
• W371889377 hasRelatedWork W2552521737 @default.
• W371889377 hasRelatedWork W2558585013 @default.
• W371889377 hasRelatedWork W2578089076 @default.
• W371889377 hasRelatedWork W2579933840 @default.
• W371889377 hasRelatedWork W2591223195 @default.
• W371889377 hasRelatedWork W2908744322 @default.
• W371889377 hasRelatedWork W2999665160 @default.
• W371889377 hasRelatedWork W2999678261 @default.
• W371889377 hasRelatedWork W3196196470 @default.
• W371889377 hasRelatedWork W3196876910 @default.
• W371889377 hasRelatedWork W3197808598 @default.
• W371889377 hasVolume "48" @default.
• W371889377 isParatext "false" @default.
• W371889377 isRetracted "false" @default.
• W371889377 magId "371889377" @default.
• W371889377 workType "article" @default.